Pharmaceutical companies like J&J, Merck, and Eli Lilly are implementing AI training for employees to boost productivity in drug development.
J&J emphasizes bilingual skills, with literacy required in specialized job skills and fluency in AI technology.
Over 56,000 J&J employees have taken generative AI training, enabling them to use AI tools for tasks like summarization and prompt engineering.
The pharmaceutical sector is shifting skill priorities towards AI expertise alongside traditional biology and chemistry knowledge.
Generative AI offers benefits in drug development by accelerating processes, improving patient selection for trials, and enhancing marketing strategies.
Companies like J&J and Merck have utilized generative AI for tasks such as drafting regulatory documents and improving efficiency in drug discovery.
AI upskilling programs have shown success at J&J, with thousands of employees participating in digital training courses focusing on AI and emerging technologies.
Merck's GPTeal platform provides access to large language models while maintaining data security, allowing employees to optimize tasks using generative AI.
Small companies like Blue Earth Therapeutics are also considering AI applications for efficiency goals, with plans to provide training as they expand.
Eli Lilly leverages generative AI for various research and documentation tasks, encouraging employees to use tools like ChatGPT responsibly while promoting AI adoption across the workforce.